Letters Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes

Authors’ reply to Patel and colleagues

BMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2927 (Published 24 May 2016) Cite this as: BMJ 2016;353:i2927
  1. Xin Sun, professor1,
  2. Gordon H Guyatt, distinguished professor2,
  3. Ling Li, research associate1
  1. 1Chinese Evidence-based Medicine Centre, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China
  2. 2Department of Clinical Epidemiology and Biostatistics and Department of Medicine, McMaster University, Hamilton, ON, Canada
  1. sunx26{at}gmail.com

We appreciate Patel and colleagues’ comments about our systematic review and meta-analysis of the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on heart failure and hospital admission for heart failure.1 2 We concluded that the relative effect on heart failure was uncertain, given the limitations of current evidence …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe